Alexion Pharmaceuticals, Inc. has initiated dosing in a single, multinational, placebo-controlled clinical trial to evaluate the efficacy and safety of eculizumab (Soliris®) for the prevention of delayed graft function (DGF) after kidney transplantation in adult patients who are at increased risk of DGF … more

Bristol-Myers Squibb Company and Pfizer Inc. report that the FDA has approved a Supplemental New Drug Application for Eliquis (apixaban) for the treatment of deep vein thrombosis and pulmonary embolism … more